We investigated the biosynthesis of electron transfer flavoprotein (ETF) in a cell-free system. Both a-(a-ETF, 32,000 molecular weight [mol wtj) and ,-subunits (fi-ETF, 27,000 mol wt) were nuclear-coded, and synthesized in the cytosol. a-ETF was synthesized as a precursor (pa-ETF), 3,000 mol wt larger than its mature counterpart, and was translocated into the mitochondria and processed to the mature a-ETF. The newly synthesized jt-ETF was the same as the mature fl-ETF. Using I35Simethionine labeling, we also studied the biosynthesis in cultured normal human fibroblasts. pa-ETF was detected when the cells were labeled in the presence of dinitrophenol or rhodamine 6G. Among six glutaric aciduria type II (GAII) and two ethylmalonic-adipic aciduria cell lines, defective pa-ETF synthesis was observed in three GAII cell lines, and ,-ETF synthesis was normal. In one of them, no pa-ETF was synthesized at all, while in another, a faint pa-ETF band of normal size was detected, and was efficiently processed. In the third line, a-ETF was 1,000 mol wt smaller than the normal counterpart, both as the precursor and as the mature form.
Introduction
Electron transfer flavoprotein (ETF)' is a soluble mitochondrial flavoprotein (1) . It is a dimer of nonidentical subunits (2) (3) (4) (5) (6) . ETF serves as a specific electron acceptor for several dehydrogenases, including five acyl-CoA dehydrogenases (1, 4, 5) , glutaryl-CoA dehydrogenase (7) , and sarcosine dehydrogenase (8) . ETF transfers electrons from the primary dehydrogenases to the main mitochondrial respiratory chain via ETF/ubiquinone oxidoreductase (ETF-dehydrogenase), an iron-sulfur flavoprotein (9) . A genetic deficiency of ETF or ETF-dehydrogenase was considered to be the cause of glutaric aciduria type II (GAII) II; NETS, NaCl/EDTA/Triton X-100/SDS buffer, pa-ETF, precursor a-ETF; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; vl, 2, and 3, variant alleles for a-ETF. (10, 11) and its milder variant, ethylmalonic-adipic aciduria (EMA) (12) . These metabolic disorders are characterized by severe acidosis, hypoglycemia, and, often, neonatal death. Large amounts of aliphatic mono-and dicarboxylic acids accumulate in blood and urine of patients with these diseases (13) . In fact, an ETF-dehydrogenase deficiency has recently been shown with the immunoblotting technique and assay of its activity, to be the cause of GAII in some patients (14). Data on remaining GAII patients suggested an ETF deficiency (14, 15) . However, the precise nature of the molecular basis of ETF deficiency remained ambiguous.
In the past several years, it has been shown that many mitochondrial matrix enzymes are nuclear-coded and synthesized on cytoplasmic polyribosomes as precursor peptides 2,000-10,000 molecular weight (mol wt) larger than the respective mature counterpart. The precursors are then translocated into the mitochondria and processed by an energy-dependent process and their extended sequence clipped (16) (17) (18) . The mechanisms of in vitro translation and posttranslational processing of the precursors by isolated mitochondria have been extensively studied for a number ofenzymes (16) (17) (18) , but those for ETF subunits have not been studied.
In this paper, we report in vitro translation of ETF in a cellfree system using rabbit reticulocyte lysate programmed by rat liver mRNA, and its posttranslational processing by isolated rat liver mitochondria. We also studied the biogenesis of ETF in normal cultured human fibroblasts and those from GAII and EMA patients. (12) .
Methods
Antibody against ETF. ETF was purified to homogeneity from rat liver mitochondria (5, 22) . Antiserum against the pure rat ETF was raised in a rabbit and partially purified as previously described (22) . The antiserum specifically precipitated both a-(a-ETF) and 6-subunits (-EThF) of ETF from rat and human liver homogenates. 100 Ml of the antiserum was capable of immunoprecipitating -20 ,g of pure ETF.
Cell-free translation andposttranslational processing. The biosynthesis ofproteins was carried out using [35S]methionine and a rabbit reticulocyte lysate translation kit according to the method suggested by the supplier, with some modifications. The translation kit was supplemented with 0.6 A260 U of calf liver tRNA and 3 1Ag of rat liver poly(A+) RNA per 100 jul of translation mixture. Rat liver RNA was prepared according to the method of Conboy et al. (23) . Poly (A') RNA was isolated using an oligo(dT) column (type 2; Collaborative Research, Lexington, MA) according to the supplier's procedure.
Posttranslational processing experiments using the isolated rat liver mitochondria were essentially carried out according to the method of Fenton et al. (24) . Mitochondria were prepared according to the method of Lowenstein et al. (25) . Freshly prepared mitochondria were suspended in a buffer consisting of 2 mM Hepes, pH 7.4, 220 mM mannitol, 70 mM sucrose, supplemented with 2 mM EGTA, 4 mM MgCl, 4 mM ADP, and 20 mM glutamate. The final concentration of mitochondrial suspension was 4 mg protein/ml. The translation mixture (30 Ml) was mixed with an equal volume of the mitochondrial suspension, and incubated at 30'C for the period indicated. After incubation, the reaction mixture was fractionated to supernatant and mitochondrial pellet. Products of the cell-free translations or processing reactions were solubilized in 9 vol of a buffer containing 150 mM NaCl, 10 mM EDTA, pH 7.4, 0.5% Triton X-100, 0.25% sodium dodecyl sulfate (SDS), and 2% unlabeled methionine (NETS/methionine-buffer), and immunoprecipitated as described below.
Labeling offibroblasts in culture. The confluent monolayer of fibroblasts in 6-cm dishes (-5 X 106 cells/dish) was labeled with [35S]methionine (50-100 MCi) in 5 ml of labeling media containing 60% Puck's saline F, 15% dialyzed fetal calf serum, and 10% glucose, as previously described (26) . The dishes were incubated at 370C for 1 h. After removal ofthe labeling medium, cells were washed with phosphate-buffered saline and harvested by adding 1 ml of NETS/methionine buffer to each dish. The solubilized cell extract was subjected to immunoprecipitation. When rhodamine 6G or dinitrophenyl (DNP) was used, they were added to the medium at a final concentration of 2.1 MM (rhodamine 6G) or 4 mM (DNP) 30 min before the medium was replaced with the labeling medium containing [35S]methionine. For pulse-labeling experiments, the cells were labeled in the same manner as described above for 1 h in the presence of4 mM DNP. After the cells were washed twice with phosphate-buffered saline, the medium was replaced with the growing medium with or without DNP.
Immunoprecipitation and SDS-polyacrylamide gel electrophoresis (PAGE). 1 ml of sample preparation solubilized by NETS/methioninebuffer was centrifuged for 30 min at 105,000 g. The supernatant was mixed with 10 Ml of anti-ETF antibody. The immune complexes were recovered by adding 10 vol of S. aureus cell suspension per volume of antibody and subsequently washed as described (26) . Slab SDS-PAGE was performed using 10% gels (0.8 mm thick) according to the method of Laemmli (27). Gels were stained with Coomassie Brilliant Blue, treated with Autofluor (National Diagnostics, Inc., Somerville, NJ), dried, and fluorographed according to the supplier's directions.
Results
Cell-free translation ofETF. When cell-free translation was carried out using [35S]methionine, rabbit reticulocyte lysate, and rat liver poly(A+) RNA, and its products were analyzed by immunoprecipitation and SDS-PAGE, two sharp radiolabeled protein bands were detected (Fig. 1, lane 2) . One of them was identical in size (27,000 mol wt) to fl-ETF. In contrast, the molecular weight of the other band (35,000 mol wt) was -3,000 mol wt larger than the a-ETF (lane 1), indicating that a-ETF was synthesized as a larger precursor (pa-ETF). Intensity of these labeled bands was very weak and only barely detectable when an excess amount of the pure rat ETF was added to the translation mixture, before the addition ofthe antiserum, to compete for the antibody with the labeled proteins (lane 3). Also, no labeled band was detected in a control (lane 4) in which antirat ETW antiserum was replaced with a nonimmune rabbit serum. (24, 28, 29) . When normal human fibroblasts were incubated with [35S]methionine in the presence of rhodamine 6G (Fig. 4) or DNP (Fig. 5 A) The time course of the processing of precursor ETF to the mature form was studied by pulse-labeling the cells with [35S]methionine in the presence of 4 mM DNP, followed by a chase after removing DNP (Fig. 5 A) . A small amount of processed a-ETF was detected at 5 min (lane 3). The half-life of pa-ETF in the conversion to the mature form was -15 min (lane 5) as judged by the parity of these two bands.
To study the stability of pa-ETF and fl-ETF in the cytosols, the cells were pulse-labeled with [35S]methionine and chased in the presence of DNP (Fig. 5 B) . The half-life of pa-ETF was slightly <1 h. The half-life of,B-ETF, under the same conditions, was between 2 and 3 h. In contrast to the relative instability of pa-ETF and ,B-ETF in the cytosol, processed a-and f3-ETF were considerably more stable in the mitochondria, as determined in the absence of DNP (Fig. 5 B, lanes 1 and 2) its heterogeneity infibroblastsfrom patients with glutaric aciduria type II. The ETF synthesis in two normal, six GAII, and two EMA cell lines were studied using the same method. First, ETF synthesis in the absence of inhibitors was tested (Fig. 6) . The intensity and molecular size of a-and 3-ETF synthesized by three GAII cell lines (1312, 1341, and 141 1) and two EMA cell lines (493 and 741) were indistinguishable from those synthesized by two normal cell lines. In contrast, marked abnormalities in the synthesis of a-ETF were found in the other three GAII cell lines. Cell line 605 did not synthesize a-ETF at all. In 1313, only a faint radiolabeled a-ETF was detected. In 1391, an a-ETF band, as intense as that ofthe normal a-ETF, was detected, but its moblity on SDS-PAGE was distinctly faster than that of normal a-ETF. In all three lines, the synthesis of the 1-subunit was well labeled and its size was normal.
In order to examine whether the defective a-ETF synthesis in the three GAII lines was due to a defect in the synthesis of the pa-ETF, or, alternatively, due to pa-ETF being synthesized but not processed properly, these cells were labeled with [35S]methionine in the presence of rhodamine 6G (Fig. 7) . In one normal and two EMA (493 and 741) cell lines, a labeled pa-ETF of 35,000 mol wt was detected. In contrast, no labeled pa-ETF was detected at all in line 605, whereas a weak but distinct radioactive pa-ETF band with normal size was detected in line 1313. In the latter, there was an additional faint band that is slightly smaller than pa-ETF. This band may represent a break-down product of pa-ETF. In this cell line, the intensity ofpa-ETF labelled in the presence ofrhodamine 6G was stronger than that of a-ETF labeled in the absence of the inhibitor. In line 1391, a clear band of radioactive pa-ETF was detected, but its size was 1,000 mol wt smaller than normal pa-ETF.
Discussion
We have shown here, using the cell-free translation system and isolated rat liver mitochondria, that rat a-ETF was synthesized in the cytosol as a precursor (35,000 mol wt) 3,000 mol wt larger than the mature counterpart (32,000 mol wt). The pa-ETF was imported into the mitochondria and processed to the mature form with its extended sequence cleaved, as in the case of many enzymes associated with the mitochondrial matrix or inner membrane (16) (17) (18) . fl-ETF was also synthesized in the cytosol and imported into the mitochondria, but it was synthesized in a form that is indistinguishable from the mature 13- size. There were no detectable changes in its molecular size during or after import. Currently, only a few mitochondrial matrix or inner membrane enzymes (proteins) in mammals are known to be synthesized in a form with the same molecular size as that of the mature enzyme. These include mitochondrial 3-oxoacylCoA thiolase (30) and adenine nucleotide translocator (31). Taking advantage ofthe fact that the anti-rat ETF antibody cross-reacts with human ETF, we studied the ETF biosynthesis in cultured human skin fibroblasts. First, we have shown that the sizes of a-(32,000 mol wt) and 13-subunits (27,000 mol wt) of human ETF were identical to the rat counterparts. As in the case ofother matrix enzymes (24, 28, 29) , posttranslational processing of the pa-ETF was inhibited by DNP and rhodamine 6G. Like rat a-ETF, human a-ETF was synthesized as a precursor (35,000 mol wt), 3,000 mol wt larger than the mature form, while the mass of the newly synthesized fl-ETF was the same as that of the mature form. The synthesis of both pa-ETF and fl-ETF was severely inhibited by cycloheximide (500 ug/ ml) but not at all by chloramphenicol (100 ,ug/ml). These results confirm that both a-and f3-ETF are nuclear-coded and synthesized in the cytosol although the molecular size ofthe latter does not change after the mitochondrial import. The half-life of pa-ETF (15 min) in the conversion to the mature form is considerably longer than that of pre-aspartate aminotransferase (30-60 s) (32), pre-ornithine carbamyltransferase (up to 2 min) (33), and short-(<5 min), medium-(5 min), and long-chain acylCoA dehydrogenases (5 min). It is similar to that of isovalerylCoA dehydrogenase (28) . pa-ETF and ,B-ETF were relatively stable in the cytosol. ,B-ETF was significantly more stable inside the mitochondria than in the cytosol.
We studied the biosynthesis of ETF in cells from six GAII patients and two EMA patients. We have shown for the first time that an abnormal a-ETF synthesis was the primary lesion causing metabolic derangements in three GAII lines. Our results indicate that there are at least three variant alleles for a-ETF. Variant 1 (vl) is incapable of producing translatable mRNA for a-ETF. Line 605 is a homozygote for this allele. vl may be due to a deletion, nonsense mutation, or a frameshift in a region close to the 5' end ofthe genome. Alternatively, vl allele produces an extremely labile messenger RNA. Variant 2 (v2) allele produces a variant pa-ETF with a normal size, as seen in line 1313. v2 precursor is processed to the variant a-ETF with a normal size in a normal fashion, suggesting that v2 is due to a point mutation in the main sequence. v2 a-ETF in line 1313 was always only faintly labeled. In contrast, its precursor was consistently more intensely labeled than the mature form, suggesting that the mature v2 a-ETF was labile. The intensity of v2 pa-ETF was still considerably weaker than normal pa-ETF. This observation and the presence ofa faint extra band that is slightly smaller than pa-ETF both suggest that v2 pa-ETF is also labile. Also, it is likely that line 1313 is a compound heterozygote for vl and v2 alleles. Alternatively, the immunoreactivity of v2 with anti-rat ETF antibody was weaker than that of normal human a-ETF. Variant 3 (v3) produces a variant a-ETF, the mobility of which on SDS-PAGE is slightly faster than normal a-ETF, suggesting that this variant a-ETF is 1,000 mol wt smaller than the normal counterpart, as seen in line 1391. Since its precursor has a leader sequence ofnormal size and it was readily processed to the mature form in a normal manner, it appears that this variant is due to a mutation in the region close to the 3' end of 
